9636 related articles for article (PubMed ID: 1515098)
1. Modulation of hematologic and immunologic effects of high dose chemotherapy by interleukin-2 in a murine tumor model.
Rinehart JJ; Triozzi PL; Lee MH; Aldrich W; Young D
Mol Biother; 1992 Jun; 4(2):77-82. PubMed ID: 1515098
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
Winkelhake JL; Stampfl S; Zimmerman RJ
Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
[TBL] [Abstract][Full Text] [Related]
3. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
[TBL] [Abstract][Full Text] [Related]
4. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.
Silagi S; Schaefer AE
J Biol Response Mod; 1986 Oct; 5(5):411-22. PubMed ID: 3490544
[TBL] [Abstract][Full Text] [Related]
5. Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin 2: characteristics of killer cells generated in situ.
Lala PK; Parhar RS
Cancer Res; 1988 Mar; 48(5):1072-9. PubMed ID: 3124954
[TBL] [Abstract][Full Text] [Related]
6. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
McIntosh JK; Mulé JJ; Krosnick JA; Rosenberg SA
Cancer Res; 1989 Mar; 49(6):1408-14. PubMed ID: 2784349
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of the tumor determines the outcome of immunotherapy with interleukin-2, ABPP, and cyclophosphamide of micro- and macrometastatic intraperitoneal tumor.
Eggermont AM; Sugarbaker PH
Cancer Detect Prev; 1990; 14(4):483-90. PubMed ID: 2224911
[TBL] [Abstract][Full Text] [Related]
8. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
[TBL] [Abstract][Full Text] [Related]
9. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.
Kedar E; Ben-Aziz R; Shiloni E
Isr J Med Sci; 1988; 24(9-10):494-504. PubMed ID: 3264551
[TBL] [Abstract][Full Text] [Related]
10. Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors.
Papa MZ; Yang JC; Vetto JT; Shiloni E; Eisenthal A; Rosenberg SA
Cancer Res; 1988 Jan; 48(1):122-9. PubMed ID: 3257159
[TBL] [Abstract][Full Text] [Related]
11. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.
Cameron RB; McIntosh JK; Rosenberg SA
Cancer Res; 1988 Oct; 48(20):5810-7. PubMed ID: 3262413
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha.
McIntosh JK; Mulé JJ; Merino MJ; Rosenberg SA
Cancer Res; 1988 Jul; 48(14):4011-7. PubMed ID: 3260130
[TBL] [Abstract][Full Text] [Related]
14. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.
Thompson JA; Peace DJ; Klarnet JP; Kern DE; Greenberg PD; Cheever MA
J Immunol; 1986 Dec; 137(11):3675-80. PubMed ID: 3491145
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model.
Hermans IF; Chong TW; Palmowski MJ; Harris AL; Cerundolo V
Cancer Res; 2003 Dec; 63(23):8408-13. PubMed ID: 14679003
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice.
Ewens A; Luo L; Berleth E; Alderfer J; Wollman R; Hafeez BB; Kanter P; Mihich E; Ehrke MJ
Cancer Res; 2006 May; 66(10):5419-26. PubMed ID: 16707470
[TBL] [Abstract][Full Text] [Related]
18. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
Lee K; O'Donnell RW; Cockett AT
J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of IL-2 activated natural killer cell adoptive immunotherapy with cyclophosphamide.
Goldfarb RH; Ohashi M; Brunson KW; Kirii Y; Kotera Y; Basse PH; Kitson RP
Anticancer Res; 1998; 18(3A):1441-6. PubMed ID: 9673353
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma.
Gautam SC; Chikkala NF; Lewis I; Grabowski DR; Finke JH; Ganapathi R
Anticancer Res; 1992; 12(3):921-5. PubMed ID: 1622150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
